Save up -80% on Erlotinib
Note: this is a drug discount program, not an insurance plan.
Price of Erlotinib
Tarceva 25 mg tablet
* price without discount in nearest pharmacy. Price may vary.
We offer free Erlotinib coupons and discounts that may help you save up to 80% off the retail price in your local pharmacy. Just print your coupon! It’s ready to use and never expire. Present your coupon in most local pharmacies to get a discount on Erlotinib. Claim your prescription drug card now!
Erlotinib volume of distribution
Apparent volume of distribution = 232 L
What is Erlotinib
Erlotinib hydrochloride (trade name Tarceva, Genentech/OSIP, originally coded as OSI-774) is a drug used to treat non-small cell lung cancer, pancreatic cancer and several other types of cancer.
Similar to gefitinib, erlotinib specifically targets the epidermal growth factor receptor (EGFR) tyrosine kinase. It binds in a reversible fashion to the adenosine triphosphate (ATP) binding site of the receptor. Erlotinib has recently been shown to be a potent inhibitor of JAK2V617F activity. JAK2V617F is a mutant of tyrosine kinase JAK2, is found in most patients with polycythemia vera (PV) and a substantial proportion of patients with idiopathic myelofibrosis or essential thrombocythemia. The study suggests that erlotinib may be used for treatment of JAK2V617F-positive PV and other myeloproliferative disorders.
Erlotinib mechanism of action
The mechanism of clinical antitumor action of erlotinib is not fully characterized. Erlotinib inhibits the intracellular phosphorylation of tyrosine kinase associated with the epidermal growth factor receptor (EGFR). Specificity of inhibition with regard to other tyrosine kinase receptors has not been fully characterized. EGFR is expressed on the cell surface of normal cells and cancer cells.
Dosage forms of Erlotinib
|Film coated tablets||Oral use||100 mg|
|Film coated tablets||Oral use||150 mg|
|Film coated tablets||Oral use||25 mg|
Humans and other mammals
Indication of Erlotinib
For the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Also for use, in combination with gemcitabine, as the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer.
Toxicity of Erlotinib
Symptoms of overdose include diarrhea, rash, and liver transaminase elevation. The most common adverse reactions (50%) in NSCLC are rash, diarrhea, anorexia and fatigue. The most common adverse reactions (50%) in pancreatic cancer are fatigue, rash, nausea and anorexia.
Disclaimer: before buying a Erlotinib on prescription, consult your health care provider. Content on this page is provided for informational purposes only. Any use of this information is at your own risk.